Lindus Health secures £14.1m Series A funding led by Creandum to scale clinical trials
Creandum led the Series A round with participation from Peter Thiel, firstminute, Seedcamp, Hambro Perks and Amino Collective.
Lindus Health runs faster end-to-end clinical trials using its proprietary technology platform and machine learning. The firm operates across the UK, US and Europe to help bring treatments for chronic conditions to patients more quickly.
Lindus Health has secured £14.1m in a Series A funding round led by Creandum. The injection of capital will support the expansion of the firm's technology platform to deliver more end-to-end clinical trials and higher quality data to research sponsors.
Participation in the round came from PayPal co-founder Peter Thiel alongside returning backers firstminute, Seedcamp, Hambro Perks and Amino Collective. The London and US based enterprise plans to scale its operations following a period of growth that has seen it deliver over 80 clinical trials across multiple territories.
From the founder
"Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly."
Michael Young
Co-Founder at Lindus Health
Investor perspective
"When we first met Michael, Meri and the rest of the Lindus Health team, we knew their approach to disrupting the clinical trials industry would be the right one. With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process. We were blown away by the work Lindus is already doing across the US, UK and Europe with stellar customer feedback and references. The potential Lindus has on improving the world’s health is vast and we are excited to join them on this journey."
Fredrik Cassel
General Partner, Creandum
Use of funds
- 01Continue product development
Investors
Categories
About the company
Lindus Health
Lindus Health operates a technology platform to run faster end-to-end clinical trials.